Citigroup Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a 'Buy' rating on Syndax Pharmaceuticals and raises the price target from $31 to $35.
July 26, 2023 | 2:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a 'Buy' rating on Syndax Pharmaceuticals and raises the price target from $31 to $35, which could potentially increase investor confidence and drive the stock price up.
The raised price target by Citigroup indicates a positive outlook for Syndax Pharmaceuticals. This could potentially increase investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100